| First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase … AV Balar, D Castellano, PH O'Donnell, P Grivas, J Vuky, T Powles, ... The Lancet Oncology 18 (11), 1483-1492, 2017 | 1246 | 2017 |
| Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: preliminary results from the phase 2 KEYNOTE-052 study A Balar, J Bellmunt, PH O'donnell, D Castellano, P Grivas, J Vuky, ... Annals of Oncology 27, vi567, 2016 | 97 | 2016 |
| Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population. AV Balar, DE Castellano, PH O'Donnell, P Grivas, J Vuky, T Powles, ... Journal of Clinical Oncology 35 (6_suppl), 284-284, 2017 | 71 | 2017 |
| Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). PH O'Donnell, P Grivas, AV Balar, J Bellmunt, J Vuky, T Powles, ... Journal of Clinical Oncology 35 (15_suppl), 4502-4502, 2017 | 67 | 2017 |
| On analysis of longitudinal clinical trials with missing data using reference-based imputation GF Liu, L Pang Journal of Biopharmaceutical Statistics 26 (5), 924-936, 2016 | 56 | 2016 |
| Comparing statistical methods for quantifying drug sensitivity based on in vitro dose–response assays S Huang, L Pang Assay and drug development technologies 10 (1), 88-96, 2012 | 53 | 2012 |
| Variance estimation in censored quantile regression via induced smoothing L Pang, W Lu, HJ Wang Computational statistics & data analysis 56 (4), 785-796, 2012 | 48 | 2012 |
| Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). J Vuky, AV Balar, DE Castellano, PH O'Donnell, P Grivas, J Bellmunt, ... Journal of Clinical Oncology 36 (15_suppl), 4524-4524, 2018 | 47 | 2018 |
| KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based … DF Bajorin, ER Plimack, AO Siefker-Radtke, TK Choueiri, R De Wit, ... Journal of Clinical Oncology 33 (15_suppl), TPS4572-TPS4572, 2015 | 15 | 2015 |
| Rheumatoid arthritis disease progression modeling R Reeve, L Pang, B Ferguson, M O’Kelly, S Berry, W Xiao Therapeutic Innovation & Regulatory Science 47 (6), 641-650, 2013 | 10 | 2013 |
| Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307. AV Balar, ER Plimack, P Grivas, A Necchi, M De Santis, L Pang, SM Keefe, ... Journal of Clinical Oncology 36 (15_suppl), TPS4587-TPS4587, 2018 | 8 | 2018 |
| Local Buckley-James estimation for heteroscedastic accelerated failure time model L Pang, W Lu, HJ Wang Statistica Sinica 25, 863, 2015 | 8 | 2015 |
| Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy … T Powles, J Bellmunt, DP Petrylak, L Fong, H Nishiyama, CN Sternberg, ... Journal of Clinical Oncology 36 (15_suppl), TPS4586-TPS4586, 2018 | 7 | 2018 |
| Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052 T Powles, J Bellmunt, D Castellano, P O’Donnell, P Grivas, J Vuky, ... European Urology Supplements 3 (16), e285-e286, 2017 | 4 | 2017 |
